CAMBRIDGE, Mass., July 24, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the "Company") (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that its second quarter 2024 financial results will be released on Wednesday, July 31, 2024, before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss the results and prov ...